10x Genomics revenue and financials
$80.66Change from previous close: −17.47%Absolute change: −$17.08
In the fiscal year ended December 2025, 10x Genomics reported revenue of $642.82M (+5.25% year over year). The net loss was $43.54M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.25%
- 2025 vs 2024
- Net margin
- -6.8%
- 2024: -29.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 643 | 611 | 619 | 516 | 490 | 299 | 246 | 146 | 71.1 |
| Cost of revenue | 199 | 196 | 209 | 120 | 74.1 | 58.5 | 61.0 | 28.7 | 10.6 |
| Gross profit | 444 | 414 | 409 | 396 | 416 | 240 | 185 | 118 | 60.5 |
| Selling, general and administrative | 310 | 343 | 343 | 296 | 258 | — | — | — | — |
| Research and development | 235 | 265 | 266 | 264 | 212 | — | — | — | — |
| Operating income | -61.0 | -195 | -265 | -168 | -52.3 | -534 | -30.6 | -111 | -18.4 |
| EBIT | -100 | -193 | -200 | -164 | -52.9 | — | — | — | — |
| EBITDA | -64.1 | -158 | -164 | -138 | -31.8 | — | — | — | — |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.5 | 0.9 | 1.7 | 3.1 | 2.4 | 0.8 |
| Pre-tax income | -39.9 | -178 | -249 | -162 | -53.7 | — | — | — | — |
| Income tax | 3.6 | 4.9 | 6.3 | 4.0 | 4.5 | 8.3 | 0.2 | 0.1 | 0.0 |
| Net income | -43.5 | -183 | -255 | -166 | -58.2 | -543 | -31.3 | -112 | -18.8 |
| Net income to common shareholders | -43.5 | -183 | -255 | -166 | -58.2 | — | — | — | — |
| Basic EPS | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | — | — |
| Diluted EPS | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | — | — |
| Average shares (basic) | 125 | 120 | 117 | 114 | 110 | — | — | — | — |
| Average shares (diluted) | 125 | 120 | 117 | 114 | 110 | 101 | 39.1 | — | — |